https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50571 Wed 28 Feb 2024 15:53:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49079 Wed 03 May 2023 16:14:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54370 Tue 20 Feb 2024 19:58:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51598 Tue 12 Sep 2023 12:25:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26115 12 years with a chronic cough of > 8 weeks' duration that was unexplained after systematic investigation and treatment were included and assessed for relevance and quality. Based on the systematic review, guideline suggestions were developed and voted on by using the American College of Chest Physicians organization methodology. Results: Eleven RCTs and five systematic reviews were included. The 11 RCTs reported data on 570 participants with chronic cough who received a variety of interventions. Study quality was high in 10 RCTs. The studies used an assortment of descriptors and assessments to identify UCC. Although gabapentin and morphine exhibited positive effects on cough-related quality of life, only gabapentin was supported as a treatment recommendation. Studies of inhaled corticosteroids (ICS) were affected by intervention fidelity bias; when this factor was addressed, ICS were found to be ineffective for UCC. Esomeprazole was ineffective for UCC without features of gastroesophageal acid reflux. Studies addressing nonacid gastroesophageal reflux disease were not identified. A multimodality speech pathology intervention improved cough severity. Conclusions: The evidence supporting the diagnosis and management of UCC is limited. UCC requires further study to establish agreed terminology and the optimal methods of investigation using established criteria for intervention fidelity. Speech pathology-based cough suppression is suggested as a treatment option for UCC. This guideline presents suggestions for diagnosis and treatment based on the best available evidence and identifies gaps in our knowledge as well as areas for future research.]]> Sat 24 Mar 2018 07:41:06 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25578 Sat 24 Mar 2018 07:35:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22197 8 weeks' duration) without active respiratory disease or infection were randomly assigned to receive gabapentin (maximum tolerable daily dose of 1800 mg) or matching placebo for 10 weeks. Block randomisation was done with randomisation generator software, stratified by sex. Patients and investigators were masked to assigned treatment. The primary endpoint was change in cough-specific quality of life (Leicester cough questionnaire [LCQ] score) from baseline to 8 weeks of treatment, analysed by intention to treat. 62 patients were randomly assigned to gabepentin (n=32) or placebo (n=30) and ten patients withdrew before the study end. Gabapentin significantly improved cough-specific quality of life compared with placebo (between-group difference in LCQ score during treatment period 1·80, 95% CI 0·56-3·04; p=0·004; number needed to treat of 3·58). Side-effects occurred in ten patients (31%) given gabapentin (the most common being nausea and fatigue) and three (10%) given placebo. The treatment of refractory chronic cough with gabapentin is both effective and well tolerated. These positive effects suggest that central reflex sensitisation is a relevant mechanism in refractory chronic cough.]]> Sat 24 Mar 2018 07:16:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54966 Mon 25 Mar 2024 12:11:04 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32503 Mon 23 Sep 2019 12:51:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36789 Mon 06 Jul 2020 11:38:40 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47886 Mon 06 Feb 2023 11:33:00 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49491 4-weeks duration) and without underlying lung disease: (1) who do not havegastrointestinal GER symptoms, should empirical treatment for GERD be used? (2) withgastrointestinal GER symptoms, does treatment for GERD resolve the cough? (3) with orwithout gastrointestinal GER symptoms, what GER-based therapies should be used and forhow long? (4) if GERD is suspected as the cause, what investigations and diagnostic criteriabest determine GERD as the cause of the cough?METHODS:We used the CHEST Expert Cough Panel’s protocol and American College ofChest Physicians (CHEST) methodological guidelines and GRADE (Grading of Recom-mendations Assessment, Development and Evaluation) framework. Delphi methodology wasused to obtain consensus.RESULTS:Few randomized controlled trials addressed thefirst two questions and noneaddressed the other two. The single meta-analysis (two randomized controlled trials)showed no significant difference between the groups (any intervention for GERDvs placebo for cough resolution; OR, 1.14; 95% CI, 0.45-2.93;P¼.78). Proton pumpinhibitors (vs placebo) caused increased serious adverse events. Qualitative data fromexisting CHEST cough systematic reviews were consistent with two international GERDguidelines.CONCLUSIONS:The panelists endorsed that: (1) treatment(s) for GERD should not be usedwhen there are no clinical features of GERD; and (2) pediatric GERD guidelines should beused to guide treatment and investigations.]]> Fri 19 May 2023 09:55:59 AEST ]]>